利来w66最给利

A multicenter, randomized, double-blind, parallel controlled clinical study of compound polymyxin B ointment combined with desonide cream in the treatment of subacute/chronic eczema

2024-09-13 0

Objective To explore the clinical efficacy and safety of Fonow ointment (Compound Polymyxin B Ointment, Triple Antibiotic Ointment) combined with desonide cream in the treatment of subacute/chronic eczema. Methods A multi-center, randomized, double-blind, parallel-controlled clinical study was conducted, and 144 patients with subacute eczema (72 patients in the experimental group and 72 patients in the control group) and 144 patients with chronic eczema (72 patients in the experimental group and 72 patients in the control group) were selected. . The experimental group and the control group were externally applied Fonow ointment (Compound Polymyxin B Ointment, Triple Antibiotic Ointment) and Fonow ointment (Compound Polymyxin B Ointment, Triple Antibiotic Ointment) base respectively. After 3 hours, both groups used desonide cream, and each was used alternately twice a day. Record the patient's symptoms/signs (including itching degree, inflammation degree, erosion/exudation degree, infiltration/hypertrophy degree and target skin lesion area) and time indicators (itch relief onset time, itching relief time). Analyze the efficacy of the two groups and evaluate safety. Results The total symptom/sign score of the test group and the control group was 7 days after treatment (subacute eczema: test group 6.09±2.78, control group 8.26±3.17; chronic eczema: test group 6.56±2.68, control group 8.84±2.90) and 14 days (Subacute eczema: 3.68±3.18 in the test group, 5.28±4.05 in the control group; Chronic eczema: 4.38±3.27 in the test group, 6.25±3.78 in the control group) were all lower than the baseline levels (Subacute eczema: 13.44±1.66 in the test group, 13.60 in the control group) ±1.75; chronic eczema: test group 12.96±1.16, control group 12.64±1.18) with varying degrees of decline. The symptoms/signs of subacute and chronic eczema patients in the experimental group were lower than those in the corresponding control group 7 and 14 days after treatment, and the differences were statistically significant (all P<0.05). Among patients with subacute eczema, the decrease in scores of itching and infiltrative hypertrophy in the test group was significantly higher than that in the control group (all P<0.01); among patients with chronic eczema, the decrease in scores of itching, infiltrative hypertrophy and target skin lesion area in the test group were significantly higher than those in the control group (all P<0.05). The onset time of itching relief in the subacute eczema patient group was shorter than that in the control group, but the itching relief time was longer than that in the control group (all P<0.05); the onset time of itching relief in the chronic eczema patient group was shorter than that in the control group (P<0.0001) , but there was no statistically significant difference in the itching relief time between the two groups. Doctors and patients in the experimental group were both more satisfied with the treatment effect than those in the control group (both P<0.05). Conclusion Topical Fonow ointment (Compound Polymyxin B Ointment, Triple Antibiotic Ointment) can enhance the efficacy of topical desonide cream in the treatment of subacute and chronic eczema, and the effect on subacute eczema is more significant. Fonow ointment (Compound Polymyxin B Ointment, Triple Antibiotic Ointment) can also better control itching symptoms and infiltration hypertrophy in patients with eczema.


Chen X , Ju M , Yu C, et al. A multicenter, randomized, double-blind, parallel controlled clinical study of compound polymyxin B ointment combined with desonide cream in the treatment of subacute/chronic eczema. Chinese Journal of Dermatology. 2016, 49(8):541-546.


To Top